Solid compositions comprising GLP-1 agonist, salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid, and lubricant

JP2024102371A5Pending Publication Date: 2024-11-01NOVO NORDISK AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024082557
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-02-02
Filing Date
2024-05-21
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Existing pharmaceutical compositions for oral administration of GLP-1 agonists suffer from poor bioavailability and rapid degradation in the gastrointestinal system, necessitating the development of improved formulations that enhance absorption and exposure.

Method used

A solid composition comprising a high content of a delivery agent, such as the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, with minimal excipients, which accelerates the absorption of GLP-1 agonists, allowing for rapid and efficient uptake.

Benefits of technology

The composition achieves accelerated absorption of GLP-1 agonists within 15-30 minutes, significantly improving plasma exposure and bioavailability through enhanced dissolution and absorption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000041_0000
    Figure 00000041_0000
  • Figure 00000041_0001
    Figure 00000041_0001
  • Figure 00000041_0002
    Figure 00000041_0002
Patent Text Reader

Abstract

To provide a pharmaceutical composition for oral administration that exhibits accelerated absorption of a GLP-1 agonist such as a GLP-1 analog comprising a substituent, thereby enabling fast and efficient uptake of the GLP-1 agonist.SOLUTION: A pharmaceutical composition comprises a GLP-1 agonist, and a delivery agent and / or absorption enhancer such as SNAC, where the delivery agent / absorption enhancer constitutes at least 90%, such as at least 95% w / w of excipients of the composition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, to a process for its preparation and to its use in medicine.

[0002] INCORPORATION BY REFERENCE TO SEQUENCE LISTING The sequence listing entitled "SEQUENCE LISTING" is 4KB, was created on January 23, 2017, and is incorporated herein by reference. [Background technology]

[0003] Human GLP-1 and its analogs have low oral bioavailability. The exposure and bioavailability of human GLP-1 and its analogs are very low after oral administration. Therefore, human GLP-1 (and its analogs) can be detected in plasma after oral administration only when formulated with certain absorption enhancers in specific amounts.

[0004] Steinert et al. (Am J Clin Nutr, October 2010, 92: 810-817) disclose oral administration of a tablet containing GLP-1(7-36) amide and 150 mg of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

[0005] WO2010 / 020978 discloses an oral pharmaceutical composition comprising a protein and N-(8-[2-hydroxybenzoyl)amino)caprylate (SNAC).Patent applications disclosing oral dosage forms of GLP-1 analogues containing salts of N-(8-(2-hydroxybenzoyl)amino]caprylate include WO2012 / 080471, WO2013 / 189988, WO2013 / 139694, WO2013 / 139695 and WO2014 / 177683.

[0006] Despite these findings, there is still room for further optimization of pharmaceutical compositions for oral administration of GLP-1 agonists, such as GLP-1 analogues containing substituents. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] WO2010 / 020978 [Patent Document 2] WO2012 / 080471 [Patent Document 3] WO2013 / 189988 [Patent Document 4] WO2013 / 139694 [Patent Document 5] WO2013 / 139695 [Patent Document 6] WO2014 / 177683 [Patent Document 7] WO98 / 08871 [Patent Document 8] WO2015 / 155151 [Patent Document 9] WO2012 / 140117 [Patent Document 10] WO2006 / 097537 [Patent Document 11] WO2011 / 080103 [Patent Document 12] WO93 / 19175 [Patent Document 13] WO96 / 29342 [Patent Document 14] WO99 / 43707 [Patent Document 15] WO99 / 43706 [Patent Document 16] WO99 / 43341 [Patent Document 17] WO99 / 43708 [Patent Document 18] WO2005 / 027978 [Patent Document 19] WO2005 / 058954 [Patent Document 20] WO2005 / 058958 [Patent Document 21] WO2006 / 005667 [Patent Document 22] WO2006 / 037810 [Patent Document 23] WO2006 / 037811 [Patent Document 24] WO2006 / 097538 [Patent Document 25] WO2008 / 023050 [Patent Document 26] WO2009 / 030738 [Patent Document 27] WO2009 / 030771 [Patent Document 28] WO2009 / 030774 [Patent Document 29] WO96 / 030036 [Patent Document 30] WO00 / 046182 [Patent Document 31] WO01 / 092206 [Patent Document 32] WO2008 / 028859 [Patent Document 33] WO2007 / 121318 [Non-patent literature]

[0008] [Non-Patent Document 1] Steinert et al. (Am J Clin Nutr, October 2010, 92: 810-817) [Non-Patent Document 2] Handbook of Pharmaceutical Excipients, 8th ed., Sheskey et al., American Pharmaceuticals Association and the Pharmaceutical Press, Royal Pharmaceutical Society of Great Britain (2017) [Non-Patent Document 3] Remington: the Science and Practice of Pharmacy, 22nd ed., Remington and Allen, Pharmaceutical Press (2013) Summary of the Invention [Means for solving the problem]

[0009] The present invention relates to a composition comprising a GLP-1 agonist and an absorption enhancer or delivery agent. In one embodiment, the composition according to the invention comprises a very high content of a delivery agent and a minimal content of further excipients, as described herein below. The provided compositions exhibit accelerated absorption, thereby allowing for rapid and efficient uptake of the active pharmaceutical ingredient.

[0010] Oral administration of therapeutic peptides is a challenge due to the rapid degradation of such peptides in the gastrointestinal system. Described herein are pharmaceutical compositions that provide accelerated absorption of GLP-1 agonists within 15-30 minutes of administration, thereby improving the exposure of GLP-1 agonists upon oral administration. The inventors have surprisingly found that formulating the compositions with very high content of absorption enhancers and minimal content of further optional excipients increases the plasma exposure of GLP-1 agonists.

[0011] In one aspect, the present invention relates to a composition in which the mass ratio of the delivery agent to the overall composition, and in particular to the other excipients of the composition, is very high.

[0012] In one embodiment, the invention relates to a pharmaceutical composition comprising a GLP-1 agonist, a delivery agent such as SNAC, and / or an absorption enhancer, wherein the delivery agent / absorption enhancer constitutes at least 90% of the excipients of the composition, e.g. at least 95% w / w.

[0013] In one embodiment, the present invention relates to a pharmaceutical composition comprising a GLP-1 agonist, a delivery agent such as SNAC and / or an absorption enhancer, wherein the delivery agent / absorption enhancer constitutes at least 90% w / w of the composition.

[0014] In a further embodiment, the composition further comprises a lubricant.

[0015] In one aspect, the present invention provides a method for producing ... pharmaceutical composition comprising the steps of: a) granulating a mixture comprising a delivery agent, a GLP-1 agonist, and optionally a lubricant; and b) compressing the granulate obtained in step a) into tablets, and optionally adding further lubricant to the granulate before compression; The present invention also relates to methods for preparing the pharmaceutical compositions described herein, such as methods comprising:

[0016] In a further aspect, the invention relates to a composition or granules as defined herein for use in medicine, such as for the treatment of diabetes or obesity, wherein said composition is to be administered orally.

[0017] In a further aspect, the present invention relates to a method for treating diabetes or obesity comprising the step of administering to a patient in need thereof a composition as defined herein, said composition being in the form of a tablet and administered orally. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 shows the rapid dissolution of A1 compared to reference A. [Diagram 2]FIG. 1 shows increased dose-corrected exposure following oral tablet administration to beagle dogs of Analogs A, B, and C when formulated according to the present invention. Data is presented as mean values. Compositions A1, B1, and C1 all demonstrate increased dose-corrected exposure relative to the reference composition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] One aspect of the invention relates to a composition comprising a GLP-1 agonist and an absorption enhancer or delivery agent. The composition may be in a form suitable for oral administration, such as a tablet, sachet or capsule. In one embodiment, the composition is an oral composition, such as an oral pharmaceutical composition, or a pharmaceutical composition.

[0020] In one embodiment, the composition according to the invention comprises a high content of a delivery agent and a minimal content of additional excipients, as described herein below. The provided compositions exhibit accelerated dissolution and accelerated absorption, allowing for rapid and efficient uptake of the active pharmaceutical ingredient.

[0021] GLP-1 The term "GLP-1 agonist" as used herein refers to a compound that fully or partially activates the human GLP-1 receptor. Therefore, this term is the same as the term "GLP-1 receptor agonist" used in other documents. The term GLP-1 agonist as well as specific GLP-1 agonists described herein are meant to include salt forms herein.

[0022] A GLP-1 agonist is required to exhibit "GLP-1 activity," which refers to the ability of a compound, i.e., a GLP-1 analog or a compound comprising a GLP-1 analog, to bind to the GLP-1 receptor and initiate a signal transduction pathway that results in insulin secretion or other physiological effects, as known in the art. In some embodiments, a "GLP-1 agonist" is an agonist that exhibits an affinity constant (K) of, e.g., less than 1 μM, e.g., less than 100 nM, as measured by methods known in the art (see, e.g., WO 98 / 08871). D ) or binds to the GLP-1 receptor with a potency (EC 50 ) and exhibits insulinotropic activity, which can be measured by in vivo or in vitro assays known to those of ordinary skill in the art. For example, a GLP-1 agonist can be administered to an animal with elevated blood glucose (e.g., obtained using an intravenous glucose tolerance test (IVGTT)). A person skilled in the art can determine, for example, depending on the animal species, an appropriate glucose administration schedule and an appropriate blood sampling schedule for the IVGTT, and measure plasma insulin concentration over time.

[0023] Suitable assays are described, for example, in WO2015 / 155151.

[0024] Half maximal effective concentration (EC 50 The term EC (Estimated Concentration of a Drug) is generally used to refer to the concentration that induces a response halfway between baseline and maximum by reference to a dose-response curve. 50 is used as a measure of the potency of a compound and represents the concentration at which 50% of its maximal effect is observed. Due to the albumin binding effect of GLP-1 agonists containing the substituents described herein, it is important to note whether the assay includes human serum albumin.

[0025] The in vitro potency of GLP-1 agonists can be determined as described in 2015 / 155151, Example 29 (without HSA) and the EC50 can be determined. 50 The lower the value, the better the potency. In one embodiment, the determined potency (EC50) (without HSA) is between 5 and 1000 pM, such as between 10 and 750 pM, between 10 and 500 pM, or between 10 and 200 pM. In one embodiment, the EC50 (without HSA) is at most 500 pM, such as at most 300 pM, such as at most 200 pM.

[0026] In one embodiment, the EC50 (without HSA) is comparable to human GLP-1(7-37).

[0027] In one embodiment, the EC50 (without HSA) is at most 50 pM. In further such embodiments, the EC50 is at most 40 pM, such as at most 30 pM, such as at most 20 pM, such as at most 10 pM. In one embodiment, the EC50 is approximately 10 pM.

[0028] In some cases, the fold change with respect to a known GLP-1 receptor agonist can be calculated as EC50(test analog) / EC50(known analog), and potency is considered equivalent when this ratio is, for example, between 0.5 and 1.5 or between 0.8 and 1.2.

[0029] In one embodiment, the potency, EC50 (without HSA) is equivalent to that of liraglutide.

[0030] In one embodiment the potency, EC50 (without HSA) is equivalent to that of semaglutide.

[0031] In one embodiment, the potency, EC50 (without HSA) is comparable to that of Compound B.

[0032] In one embodiment, the potency, EC50 (without HSA) is comparable to that of Compound C.

[0033] In some embodiments, the GLP-1 agonist is a GLP-1 analog, optionally containing one substitution. The term "analog" as used herein with reference to a GLP-1 peptide (hereinafter "peptide") refers to a peptide in which at least one amino acid residue of the peptide has been replaced by another amino acid residue and / or at least one amino acid residue has been deleted from the peptide and / or at least one amino acid residue has been added to the peptide and / or at least one amino acid residue of the peptide has been modified. Such addition or deletion of an amino acid residue may occur at the N-terminus of the peptide and / or at the C-terminus of the peptide. In some embodiments, a simple nomenclature is used to describe the GLP-1 agonist, for example, [Aib8]GLP-1(7-37) designates an analog of GLP-1(7-37) in which the naturally occurring Ala at position 8 is replaced by Aib. In some embodiments, the GLP-1 agonist comprises up to 12, e.g., up to 10, 8 or 6 amino acids that are altered, e.g., by substitution, deletion, insertion and / or modification, e.g., compared to GLP-1(7-37). In some embodiments, the analog comprises up to 10 substitutions, deletions, additions and / or insertions, e.g., up to 9 substitutions, deletions, additions and / or insertions, up to 8 substitutions, deletions, additions and / or insertions, up to 7 substitutions, deletions, additions and / or insertions, up to 6 substitutions, deletions, additions and / or insertions, up to 5 substitutions, deletions, additions and / or insertions, up to 4 substitutions, deletions, additions and / or insertions, or up to 3 substitutions, deletions, additions and / or insertions, e.g., compared to GLP-1(7-37). Unless otherwise specified, GLP-1 comprises only L-amino acids.

[0034] In some embodiments, the term "GLP-1 analog" or "analog of GLP-1" as used herein refers to a peptide or compound that is a variant of human glucagon-like peptide-1 (GLP-1(7-37)). GLP-1(7-37) has the sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 1). In some embodiments, the term "variant" refers to a compound that includes one or more amino acid substitutions, deletions, additions and / or insertions.

[0035] In one embodiment, the GLP-1 agonist exhibits at least 60%, 65%, 70%, 80% or 90% sequence identity to GLP-1(7-37) over the entire length of GLP-1(7-37). An example of a method for determining sequence identity between two analogs is to align the two peptides [Aib8]GLP-1(7-37) and GLP-1(7-37). The sequence identity of [Aib8]GLP-1(7-37) to GLP-1(7-37) is obtained by dividing the number of aligned identical residues minus the number of different residues by the total number of residues in GLP-1(7-37). Thus, in the above example, the sequence identity is (31-1) / 31.

[0036] In one embodiment, the C-terminus of the GLP-1 agonist is an amide.

[0037] In some embodiments, the GLP-1 agonist is GLP-1(7-37) or GLP-1(7-36)amide. In some embodiments, the GLP-1 agonist is exendin-4, the sequence of which is HGEGTFITSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 2).

[0038] In order to prolong the effect of the GLP-1 agonist, it is preferred that the GLP-1 agonist has an extended half-life, which can be determined by methods known in the art and in a suitable model, such as in male Sprague Dawley rats or minipigs as described in WO2012 / 140117.

[0039] In one embodiment, the GLP-1 agonist according to the invention has a half-life in minipigs of more than 24 hours. In one embodiment, the GLP-1 agonist according to the invention has a half-life in minipigs of more than 30 hours, such as more than 36 hours, for example more than 42 hours, such as more than 48 hours, for example more than 54 hours or such as more than 60 hours.

[0040] In some embodiments, the GLP-1 agonist comprises a substituent covalently attached to the peptide. In some embodiments, the substituent comprises a fatty acid or a fatty diacid. In some embodiments, the substituent comprises a C16, C18, or C20 fatty acid. In some embodiments, the substituent comprises a C16, C18, or C20 fatty diacid.

[0041] In some embodiments, the substituent is of formula (X):

[0042] [ka]

[0043] wherein n is at least 13, e.g., n is 13, 14, 15, 16, 17, 18, or 19. In some embodiments, the substituent comprises formula (X) wherein n is in the range of 13 to 19, e.g., in the range of 13 to 17. In some embodiments, the substituent comprises formula (X) wherein n is 13, 15, or 17. In some embodiments, the substituent comprises formula (X) wherein n is 13. In some embodiments, the substituent comprises formula (X) wherein n is 15. In some embodiments, the substituent comprises formula (X) wherein n is 17.

[0044] In some embodiments, the substituent is of formula (XIa) HOOC-(C6H4)-O-(CH2) m -CO-* (XIa) (wherein m is an integer ranging from 6 to 14).

[0045] In some embodiments, the substituent is of formula (XIb):

[0046] [ka]

[0047] where the carboxy group is at position 2, 3 or 4 of the (C6H4) group, and m is an integer ranging from 8 to 11.

[0048] In some embodiments, the substituent comprises formula (XIa) or formula (XIb), where m is in the range of 6 to 14, such as in the range of 8 to 11. In some embodiments, the substituent comprises formula (XIa) or formula (XIb), where m is 8, 10 or 12. In some embodiments, the substituent comprises formula (XIa) or formula (XIb), where m is 9. In some embodiments, the substituent comprises formula (XIa) or formula (XIb), where m is 11.

[0049] In some embodiments, the substituent comprises one or more 8-amino-3,6-dioxaoctanoic acids (OEGs), for example, two OEGs.

[0050] In some embodiments, the substituent is [2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl].

[0051] In some embodiments, the substituent is [2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl].

[0052] In some embodiments, the GLP-1 agonist is semaglutide, also known as N-epsilon 26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8, Arg34]GLP-1(7-37) (SEQ ID NO: 4), which has the following structure:

[0053] [ka]

[0054] and can be prepared as described in WO2006 / 097537, Example 4.

[0055] In one embodiment, the GLP-1 agonist is GLP-1 agonist B, which is shown in Example 2 of WO2011 / 080103 and has the following structure:

[0056] [ka]

[0057] With N ε26 -{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}-ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl},N ε37 -{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]-acetyl}-[Aib 8 , Arg 34 , Lys 37 The peptide is diacylated [Aib8, Arg34, Lys37]GLP-1(7-37) (SEQ ID NO:5), designated [Aib8, Arg34, Lys37]GLP-1(7-37)-peptide.

[0058] In one embodiment, the GLP-1 agonist is GLP-1 agonist C, which is shown in Example 31 of WO2012 / 140117 and has the following structure:

[0059] [ka]

[0060] With N ε27 -[2-[2-[2-[[2-[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]-acetyl], N ε36 The diacylated [Aib8, Glu22, Arg26, Lys27, Glu30, Arg34, Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly (SEQ ID NO: 6) has been designated -[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]-butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]-[Aib8, Glu22, Arg26, Lys27, Glu30, Arg34, Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly.

[0061] In general, the term GLP-1 agonist is meant to encompass a GLP-1 agonist and any pharma- ceutically acceptable salts, amides, or esters thereof. In some embodiments, the composition comprises a GLP-1 agonist or a pharma- ceutically acceptable salt, amide, or ester thereof. In some embodiments, the composition comprises a GLP-1 agonist and one or more pharma- ceutically acceptable counterions.

[0062] In some embodiments, the GLP-1 agonist is selected from the group consisting of WO93 / 19175, WO96 / 29342, WO98 / 08871, WO99 / 43707, WO99 / 43706, WO99 / 43341, WO99 / 43708, WO2005 / 027978, WO2005 / 058954, WO2005 / 058958, WO2006 / WO2009 / 030771 and WO2009 / 030774.

[0063] In some embodiments, the GLP-1 agonist is selected from the group consisting of N-epsilon 37{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37)amide; N-epsilon 26{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,Arg 34]GLP-1-(7-37);N-epsilon 37{2-[2-(2-{2-[2-((S)-3-carboxy-3-{[1-(19-carboxy-nonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-[2-(2-[2-(2-((R)-3-[1-(17-carboxyheptadecanoyl)piperidin-4-ylcarbonylamino]3-carboxypropionylamino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy]acetyl][,desaminoHis7,Glu22 Arg26,Arg34,Phe(m-CF3)28]GLP-1-(7-37)amide;N-epsilon 26-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyryl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-{4-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]butyryl}[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37); N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy]acetyl][Aib8,Arg34]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg34,Lys37] g26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({4-[(trans-19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 26[2-(2-{2-[(2-{2-[(S)-4 -Carboxy-4-({4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl[Aib8,Lys26]GLP-1(7-37)amide;N-epsilon 26[2-(2-[2-(2-[2-(2-((S)-2-[trans-4-((9-carboxynonadecanoylamino)methyl)cyclohexylcarbonylamino]-4-carboxybutanoyl N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexane-carbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][DesaminoHis7,Arg 26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{4-[4-(16-(1H-tetrazol-5-yl)-hexadecanoylsulfamoyl)butyrylamino]-butyrylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]-butyrylamino}butyrylamino]ethoxy}ethoxy)acetyl] N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37); );N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{4-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]butyrylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-34);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]butyrylamino}butyrylamino]ethoxy}ethoxy)acetyl N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-34);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-35); N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-35);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino]ethoxy}ethoxy)acetyl N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-36)amide;N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-35);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]dodecanoylamino}butyryl-amino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Lys33,Arg34]GLP-1-(7-34);N-epsilon 26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-36)amide; -[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy no]ethoxy}ethoxy)acetyl][Aib8,Lys26,Arg34]GLP-1-(7-36)amide;N-epsilon 37-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg3 4,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxy-nonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37)amide;N-epsilon 37{2-[2-(2-{2-[2-((S)-3-carboxy-3-{[1-(19-carboxy N-epsilon 37-[2-(2-[2-(2-[2-(2-((R)-3-[1-(17-carboxyhepta-decanoyl)piperidine-4-ylcarbonylamino]3-carboxy-propionylamino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy]acetyl[Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-[2-(2-[2-(2-((R)-3-[1-(17-carboxyhepta-decanoyl)piperidine-4-ylcarbonylamino]3-carboxy-propionylamino)ethoxy)ethoxy]acetyl N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22 ,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexane-carbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-[ 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexane-carbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-[2-(2 -{2-[(S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[(S )-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-(3-((2-(2-(2-(2-; (2-Hexadecyloxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propionyl)[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37)-amide;N-epsilon 37-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4-carboxybutyryl-amino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37)amide amide;N-epsilon 37-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4-carboxy-butyryl-amino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(octadecanoyl-amino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)eth N-epsilon 37-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyryl][DesaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(19-carboxynonadecanoylamino)butyrylamino]ethoxy}ethoxy )acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-(2-{2-[2-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyrylamino]butyrylamino}butyrylamino)ethoxy]ethoxy}acetyl)[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-{2-[2-(2-{(S)-4-[(S)-4-(12-{4-[16-(2-tert-butyl-2H-tetrazol-5-yl)-hexadecanoylsulfamoyl]butyrylamino}dodecanoylamino)-4-carboxybutyrylamino]-4-carboxybutyrylamino}ethoxy)ethoxy]acetyl}[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37); -{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-alpha37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]- N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][Aib8,Glu22,Arg26,Arg34,Epsilon-Lys37]GLP-1-(7-37) peptide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][DesaminoHis7, Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 36-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys36]GLP-1-(7-37)-Glu-Lys peptide;N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyryl-amino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37);N-epsilon 37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyryl-amino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37); GLP-1-(7-37);N-epsilon 37-[(S)-4-carboxy-4-(2-{2-[2-(2-{2-[2-(17-carboxyheptadecanoylamino)ethoxy]ethoxy}acetylamino)butyryl][Aib8,Glu22,Arg26,34,Lys37] GLP-1(7-37);N-epsilon 37-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][ImPr7,Glu22,Arg26,34,Lys37], GLP-1-(7-37);N-epsilon 26-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy} N-epsilon 37-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxy-phenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl}-[Aib8,Arg34,Lys37]GLP-1(7-37)-OH; N-epsilon 26(17-carboxyhepta-decanoyl)-[Aib8,Arg34]GLP-1-(7-37)-peptide;N-epsilon 26-(19-carboxynonadecanoyl)-[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-(4-{[N-(2-carboxyethyl)-N-(15-carboxypentadecanoyl)amino]methyl}benzoyl[Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethyl ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(19-carboxynonadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyhept ... ]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][3-(4-imidazolyl)propionyl 7,Arg34]GLP-1-(7-37;N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-(carboxymethyl-amino)acetylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37;N-epsilon 26-[2-(2-[2-(2-[2-[2- (2-[4-(17-carboxyheptadecanoylamino)-3(S)-sulfopropionylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-amide;N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl] Aib8,Arg34,Pro37]GLP-1-(7-37)amide;Aib8,Lys26(N-epsilon26-{2-(2-(2-(2-[2-(2-(4-(pentadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}),Arg34)GLP-1 H(7-37)-OH;N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-{[N-(2-carboxyethyl)-N-(17-carboxyheptadecanoyl)amino]methyl}benzoyl)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37);N-alpha7-formyl,N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37);N-epsilon 262 6-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Glu22,Arg34]GLP-1-(7-37);N-epsilon 26{3-[2-(2-{2-[2-(2-{2-[2-(2-[4-(15-(N-((S)-1,3-dicarboxypropyl)carbamoyl)pentadecanoylamino)-(S)-4-carboxybutyrylamino]ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propionyl}[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-{[N-(2-carboxyethyl)-N-(17-carboxy-heptadecanoyl)amino]methyl}benzoyl)amino](4(S)-carboxybutyryl-amino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37);N-epsilon 26-{(S)-4-carboxy-4-( ... -(19-carboxy-nonadecanoylamino)butyrylamino)butyrylamino)butyrylamino)butyrylamino}[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxybutyryl-[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-{3-[2-(2-{2-[2-(2-{2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino] ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propionyl}[Aib8,Arg34]GLP-1-(7-37);N-epsilon 26-{2-(2-(2-(2-[2-(2-(4-(17-carboxyheptadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[Aib8,22,27,30,35,Arg34,Pro37,Lys26]GLP-1(7-37)amide;N-epsilon 26-[ 2-(2-[2-[4-(21-carboxyuneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37); and N-epsilon 26-[2-(2-[2-(2-[2-(2-[4-(21-carboxyuneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37).

[0064] Delivery Agent Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid The delivery agent used in the present invention is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC). The structural formula of N-(8-(2-hydroxybenzoyl)amino)caprylate is given by formula (I):

[0065] [ka]

[0066] As shown in.

[0067] In some embodiments, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid comprises one monovalent cation, two monovalent cations, or one divalent cation. In some embodiments, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of sodium, potassium, and / or calcium salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. In one embodiment, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of sodium, potassium, and / or ammonium salts. In one embodiment, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is the sodium or potassium salt. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid can be prepared, for example, using the methods described in WO96 / 030036, WO00 / 046182, WO01 / 092206 or WO2008 / 028859.

[0068] The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid can be crystalline and / or amorphous. In some embodiments, the delivery agent comprises an anhydrate, monohydrate, dihydrate, trihydrate, solvate, or trihydrate of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and combinations thereof. In some embodiments, the delivery agent is a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid described in WO2007 / 121318.

[0069] In some embodiments, the delivery agent is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (herein referred to as "SNAC"), also known as sodium 8-(salicyloylamino)octanoate.

[0070] composition The composition or pharmaceutical composition of the present invention is a solid or dry composition suitable for administration by the oral route as further described herein below.

[0071] In some embodiments, the composition comprises at least one pharma- ceutically acceptable excipient. As used herein, the term "excipient" refers broadly to any ingredient other than the therapeutically active ingredient or active pharmaceutical ingredient (API). An excipient can be a pharma- ceutically inert, inactive, and / or therapeutically or medicinally non-active substance.

[0072] Excipients can serve various purposes, for example, as carriers, vehicles, fillers, binders, lubricants, glidants, disintegrants, flow regulators, crystallization inhibitors, solubilizers, stabilizers, colorants, flavorings, surfactants, emulsifiers, or combinations thereof, and / or to improve administration and / or absorption of therapeutically active substances or active pharmaceutical ingredients. The amount of each excipient used can vary within ranges conventional in the art. Techniques and excipients that can be used to formulate oral dosage forms are described in Handbook of Pharmaceutical Excipients, 8th Edition, Sheskey et al., Ed., American Pharmaceuticals Association and the Pharmaceutical Press, Royal Pharmaceutical Society of Great Britain Publishing Company (2017); and Remington: the Science and Practice of Pharmacy, 22nd Edition, Remington and Allen, Ed., Pharmaceutical Press, Inc. (2013).

[0073] In some embodiments, the excipients include binders, such as polyvinylpyrrolidone (povidone); fillers, such as cellulose powder, microcrystalline cellulose, cellulose derivatives such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxy-propylmethylcellulose, dibasic calcium phosphate, corn starch, pregelatinized starch, and the like; lubricants and / or glidants, such as stearic acid, magnesium stearate, sodium stearyl fumarate, glycerol tribehenate, and the like; flow control agents, such as colloidal silica, tallow, sorbitol ... solubilizing agents, such as pluronic, povidone, etc.; colorants, including dyes and pigments, such as red or yellow iron oxide, titanium dioxide, talc, etc.; pH adjusters, such as citric acid, tartaric acid, fumaric acid, sodium citrate, dibasic calcium phosphate, dibasic sodium phosphate, etc.; surfactants and emulsifiers, such as pluronic, polyethylene glycol, sodium carboxymethylcellulose, polyethoxylated and hydrogenated castor oil, etc.; and mixtures of two or more of these excipients and / or adjuvants.

[0074] The composition may include binders such as povidone; starch; cellulose and its derivatives, such as microcrystalline cellulose, such as Avicel PH from FMC Corp. (Philadelphia, PA), hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropyl methylcellulose METHOCEL from Dow Chemical Corp. (Midland, MI); sucrose; dextrose; corn syrup; polysaccharides; and gelatin. The binder may be selected from the group consisting of dry binders and / or wet granulation binders. Suitable dry binders are, for example, cellulose powder and microcrystalline cellulose, such as Avicel PH 102 and Avicel PH 200. In some embodiments, the composition includes Avicel, such as Avicel PH 102. Suitable binders for wet or dry granulation are corn starch, polyvinylpyrrolidone (povidone), vinylpyrrolidone-vinyl acetate copolymer (copovidone), and cellulose derivatives such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxyl-propylmethylcellulose. In some embodiments, the composition comprises povidone.

[0075] In some embodiments, the composition comprises a filler, which may be selected from lactose, mannitol, erythritol, sucrose, sorbitol, calcium phosphate, e.g., calcium hydrogen phosphate, microcrystalline cellulose, powdered cellulose, refined powdered sugar, compressible sugar, dextrates, dextrin and dextrose. In some embodiments, the composition comprises microcrystalline cellulose, e.g., Avicel PH 102 or Avicel PH 200.

[0076] In some embodiments, the composition comprises a lubricant and / or glidant. In some embodiments, the composition comprises a lubricant and / or glidant, such as talc, magnesium stearate, calcium stearate, zinc stearate, glyceryl behenate, glyceryl dibehenate, behenoyl polyoxyl-8 glyceride, polyethylene oxide polymer, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, stearic acid, hydrogenated vegetable oil, silicon dioxide, and / or polyethylene glycol. In some embodiments, the composition comprises magnesium stearate or glyceryl dibehenate (e.g. Compritol® 888 ATO product, which consists of mono-, di- and triesters of behenic acid (C22) with the diester fraction predominating).

[0077] In some embodiments, the composition comprises a disintegrant, such as sodium starch glycolate, polacrilin potassium, sodium starch glycolate, crospovidone, croscarmellose, sodium carboxymethylcellulose, or dried cornstarch.

[0078] The composition may contain one or more surfactants, for example, one surfactant, at least one surfactant, or two different surfactants. The term "surfactant" refers to any molecule or ion composed of a water-soluble (hydrophilic) portion and a fat-soluble (lipophilic) portion. The surfactant may be selected, for example, from the group consisting of anionic surfactants, cationic surfactants, nonionic surfactants, and / or zwitterionic surfactants.

[0079] As shown in the examples herein, the composition of the present invention has a very high content of delivery agent. This very high content can be determined with respect to the total content of the tablet, including the active pharmaceutical ingredient (i.e., GLP-1 agonist), or with respect to the total content of excipients excluding the active pharmaceutical ingredient. The following description also refers to a composition consisting of a specific ingredient, a GLP-1 agonist and an excipient, but it should be understood that the term consisting of still includes any substance in trace amounts that does not affect the function of the composition in any way, and such a situation may also be referred to as consisting essentially of. Such substances may be impurities remaining during the preparation of the GLP-1 agonist, or impurities from the formation of salts of NAC, or from any pharma-ceutically acceptable excipients in minimal amounts (less than 1%) that do not affect the quality or absorption of the formulation.

[0080] In one embodiment, the pharmaceutical composition comprises: a. GLP-1 agonists and b. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) Including, Said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 90% w / w or more than 90% w / w of the composition.

[0081] In further such embodiments, the salt of NAC constitutes more than 91 w / w%, such as more than 92 w / w%, for example more than 93 w / w%, such as more than 94 w / w%, for example more than 95 w / w% of the composition.

[0082] In further such embodiments, the salt of NAC constitutes at least 91 w / w%, such as at least 92 w / w%, for example at least 93 w / w%, such as at least 94 w / w%, for example at least 95 w / w% of the composition.

[0083] In one embodiment, the pharmaceutical composition comprises: a. GLP-1 agonists and b. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) Including, Said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 90 w / w% of the excipients of the composition.

[0084] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) excipients; wherein the excipient is i. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) and ii. one or more further excipients and Said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 90 w / w% of the excipients of the composition.

[0085] In further such embodiments, the salt of NAC constitutes at least 91 w / w%, such as at least 92 w / w%, for example at least 93 w / w%, such as at least 94 w / w%, for example at least 95 w / w% of the excipients of the composition.

[0086] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC); Including, Said salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitute at least 95 w / w% of the excipients of the composition.

[0087] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) excipients; wherein the excipient is i. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) and ii. one or more further excipients and Said salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitute at least 95 w / w% of the excipients of the composition.

[0088] In further such embodiments, the salt of NAC constitutes more than 95 w / w% of the composition, such as more than 96 w / w%, such as more than 97 w / w%, or such as more than 98 w / w%.

[0089] In further such embodiments, the salt of NAC constitutes at least 95 w / w% of the excipients of the composition, such as at least 96 w / w%, such as at least 97 w / w%, or such as at least 98 w / w%.

[0090] As mentioned above, the content of excipients other than the delivery agent is preferably minimal according to the present invention. In one embodiment, the pharmaceutical composition comprises at least one lubricant.

[0091] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists, b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) and c) at least one lubricant It comprises or consists of:

[0092] In such embodiments, the lubricant may be magnesium stearate or glyceryl dibehenate. In one embodiment, the lubricant is magnesium stearate. In one embodiment, the lubricant is glyceryl dibehenate.

[0093] The above composition, in which the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 95 w / w% of the composition's excipients, can further be a composition in which the salt constitutes at least 90 w / w% or more than 90 w / w% of the composition.

[0094] Similarly, the above composition in which the salt constitutes at least 90 w / w% or more than 90 w / w% of the composition can further be a composition in which the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 95 w / w% of the excipients of the composition.

[0095] The pharmaceutical composition may further be a composition in which the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) is selected from the group consisting of sodium, potassium and / or calcium salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), or just the group consisting of sodium and potassium salts. In one embodiment, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate.

[0096] In embodiments where the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 90 w / w% of the composition's excipients, the composition comprises up to 10 w / w% of additional optional excipients, such as binders, fillers, and / or lubricants / glidants. In some embodiments, the composition comprises at least 90 w / w% or more than 90 w / w% of a delivery agent and less than 5 w / w% of additional optional excipients, such as binders, fillers, and / or lubricants / glidants. In one embodiment, the pharmaceutical composition comprises at least 90 w / w% of a delivery agent and less than 5 w / w% of a lubricant. In one embodiment, the pharmaceutical composition comprises at least 90 w / w% of a delivery agent and less than 3 w / w% of a lubricant.

[0097] In some embodiments, the composition comprises at least or more than 90 w / w% of a delivery agent and 0.1-5 w / w%, such as 0.5-4 w / w% or 1-3 w / w% of a lubricant, hi further such embodiments, the composition comprises 2-2.5 w / w% of a lubricant.

[0098] In embodiments where the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) constitutes at least 95 w / w% of the composition's excipients, the composition comprises up to 5 w / w% of additional optional excipients, such as binders, fillers, and / or lubricants / glidants. In some embodiments, the composition comprises at least 95 w / w% of a delivery agent and less than 5 w / w% of a lubricant. In one embodiment, the pharmaceutical composition comprises at least 95 w / w% of a delivery agent and less than 3 w / w% of a lubricant.

[0099] In some embodiments, the composition comprises at least 95 w / w% delivery agent and 0.1-5 w / w%, such as 0.5-4 w / w% or 1-3 w / w% lubricant, hi further such embodiments, the composition comprises 2-2.5 w / w% lubricant.

[0100] The pharmaceutical compositions according to the invention are preferably made in a dosage form suitable for oral administration as described herein below. In the following, absolute amounts of the components of the compositions of the invention are provided based on the content per dosage unit, i.e. per tablet, capsule or sachet.

[0101] In a further embodiment, the pharmaceutical composition of the invention may contain up to 1000 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid per dosage unit. In one embodiment, the invention relates to a composition, wherein the dosage unit contains up to 500 mg of said salt.

[0102] In some embodiments, the amount of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid per dosage unit is at least 0.05 mmol, such as at least 0.075 mmol, such as at least 0.1 mmol, such as at least 0.125 mmol, such as at least 0.15 mmol, such as at least 0.20 mmol, at least 0.25 mmol, at least 0.30 mmol, at least 0.35 mmol, at least 0.40 mmol, at least 0.45 mmol, at least 0.50 mmol, at least 0.55 mmol or at least 0.60 mmol.

[0103] In some embodiments, the amount of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid per dosage unit of the composition is at most 3 mmol, such as at most 2.75 mmol, such as at most 2.5 mmol, for example at most 2.25 mmol, such as 2 mmol, for example at most 1.5 mmol, at most 1 mmol, at most 0.75 mmol, at most 0.6 mmol, at most 0.5 mmol, at most 0.4 mmol, at most 0.3 mmol and at most 0.2 mmol.

[0104] In some embodiments, the amount of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid per dosage unit of the composition ranges from 0.05 to 3 mmol, 0.10 to 2.5 mmol, 0.15 to 2.0 mmol, 0.20 to 1.5 mmol, 0.25 to 1.0 mmol, 0.30 to 0.75 mmol, or for example 0.45 to 0.65 mmol.

[0105] In some embodiments, when the salt of NAC is SNAC, the amount of SNAC in the composition is at least 20 mg, such as at least 25 mg, such as at least 50 mg, such as at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 175 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, and at least 300 mg per dosage unit.

[0106] In some embodiments, when the salt of NAC is SNAC, the amount of SNAC in the composition is up to 800 mg, such as up to 600 mg, such as up to 575 mg, such as up to 550 mg, up to 525 mg, up to 500 mg, up to 475 mg, up to 450 mg, up to 425 mg, up to 400 mg, up to 375 mg, up to 350 mg, up to 325 mg units, or up to 300 mg per dosage unit.

[0107] In some embodiments, when the salt of NAC is SNAC, the amount of SNAC in the composition ranges from 20 to 800 mg, such as 25 to 600 mg, for example 50 to 500 mg, for example 50 to 400 mg, for example 75 to 400 mg, for example 80 to 350 mg, or such as from about 100 to about 300 mg per dosage unit.

[0108] In one embodiment, when the salt of NAC is SNAC, the amount of SNAC is in the range of 20-200 mg, such as 25-175 mg, such as 75-150 mg, such as 80-120 mg, such as approximately 100 mg per dosage unit.

[0109] In one embodiment, when the salt of NAC is SNAC, the amount of SNAC is in the range of 200-800 mg, such as 250-400 mg, such as 250-350 mg, such as 275-325 mg, such as approximately 300 mg per dosage unit.

[0110] In one embodiment, a dosage unit of the pharmaceutical composition of the present invention contains 0.1 to 100 mg or 0.2 to 100 mg of the GLP-1 agonist.

[0111] In some embodiments, a dosage unit of the composition comprises an amount of GLP-1 agonist ranging from 0.2 to 50 mg or from 1 to 40 mg.

[0112] In some embodiments the dosage units comprise 0.5-5 mg, such as 0.75-4.5 mg, for example 1, 1.5, 2, 2.5 or 3 mg or 3.5, 4, 4.5 mg, for example 1-3 or 3-5 mg of GLP-1 agonist per dosage unit.

[0113] In some embodiments the dosage units comprise 2 to 20 mg of GLP-1 agonist, such as 2 to 15 mg, for example 2, 3, 4, 5, 6 or 7 mg, for example 2, 3, 4 or 5 mg, or for example 8, 10, 12 or 14 mg, such as 15 mg or for example 20 mg of GLP-1 agonist per dosage unit.

[0114] In some embodiments the dosage units comprise 5-50 mg of GLP-1 agonist, such as 10-45 mg, for example 20, 30 or 40 mg, or such as 25, 35 or 45 mg, or such as 30-50 mg or such as 20-40 mg of GLP-1 agonist per dosage unit.

[0115] The amount of GLP-1 agonist may vary depending on the identity of the GLP-1 agonist and the desired effect, i.e., a higher amount may be appropriate for treating obesity compared to diabetes.

[0116] In a preferred embodiment, a unit dose of the composition comprises from 0.5 to 25 mg magnesium stearate, such as from 1 to 10 mg, such as from 2 to 8 mg, or such as from 2 to 5 mg.

[0117] In a preferred embodiment, the amount of magnesium stearate is determined relative to the amount of the salt of NAC, such as SNAC, such that a unit dose of the composition contains 1-8 mg magnesium stearate, or such as 2-5 mg magnesium stearate or 2-3 mg magnesium stearate per 100 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, such as SNAC.

[0118] In a preferred embodiment, a unit dose of the composition comprises 80-120 mg of SNAC, 0.5-5 mg of a GLP-1 agonist, and 2-3 mg of a lubricant.

[0119] In a preferred embodiment, a unit dose of the composition comprises 80-120 mg of SNAC, 1.5-10 mg of a GLP-1 agonist, and 2-3 mg of a lubricant.

[0120] In a preferred embodiment, a unit dose of the composition comprises 80-120 mg of SNAC, 5-50 mg of a GLP-1 agonist, and 2-3 mg of a lubricant.

[0121] In a preferred embodiment, a unit dose of the composition comprises 250-350 mg of SNAC, 0.5-5 mg of a GLP-1 agonist, and 3-10 mg of a lubricant.

[0122] In a preferred embodiment, a unit dose of the composition comprises 250-350 mg of SNAC, 1.5-10 mg of a GLP-1 agonist, and 3-10 mg of a lubricant.

[0123] In a preferred embodiment, a unit dose of the composition comprises 250-350 mg of SNAC, 5-50 mg of a GLP-1 agonist, and 3-10 mg of a lubricant.

[0124] In one embodiment, the pharmaceutical composition of the present invention has a rapid release in vitro. The release or dissolution can be tested as known in the art and as described herein in Assay I. The release can be expressed as the amount of GLP-1 agonist measured in solution after a given period of time relative to the total content of GLP-1 agonist in the composition. The relative amount can be given as a percentage. In one embodiment, the release of GLP-1 agonist from the pharmaceutical composition of the present invention is at least 85% within 15 minutes or at least 95% within 30 minutes. In one such embodiment, the release is measured at pH 6.8.

[0125] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, The release of the GLP-1 agonist reaches 85% within 15 minutes or 95% within 30 minutes, hi one embodiment, the release is measured at pH 6.8.

[0126] In one embodiment, the pharmaceutical compositions of the present invention provide early exposure in vivo. In one embodiment, the pharmaceutical compositions of the present invention provide increased exposure in vivo. In one embodiment, the pharmaceutical compositions of the present invention provide increased early exposure in vivo. Such in vivo exposure can be tested in relevant models, such as Assay III described herein. As can be seen in table 3.1, the compositions disclosed herein have been demonstrated to increase dose-corrected early exposure in beagle dogs within the first 30 minutes after oral administration. Additionally, exposure can be measured over a defined period of time, such as t=0 to 30 minutes, as also provided in table 3.1 for the compositions described herein, and cumulative dose-corrected exposure (AUC) can be calculated.

[0127] In one embodiment the invention relates to a pharmaceutical composition, in which the dose corrected exposure at t=30 min is increased relative to a composition as described in WO2013 / 139694 comprising the further excipients microcrystalline cellulose and povidone.A reference composition of a given GLP-1 agonist is preferably prepared using the two granules disclosed in WO2013 / 139694 for forms F and H, by substituting semaglutide / compound A with the GLP-1 agonist of interest.

[0128] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, Dose corrected exposure at t=30 min is increased for the Form F / H composition of WO2013 / 139694.

[0129] In one embodiment, the pharmaceutical composition comprises: a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, Dose-adjusted exposure (AUC) from t=0 to 30 minutes is increased for the F / H compositions of WO2013 / 139694.

[0130] In one embodiment, the dose-corrected exposure (AUC) from t=0 to 30 minutes is increased by at least 1.5-fold, such as 2-fold, compared to the Form F / H composition of WO2013 / 139694.

[0131] Dosage form The composition can be administered in several dosage forms, for example, as a tablet; a coated tablet; a sachet or a capsule, such as a hard or soft shell capsule.

[0132] The composition may further be formulated with a drug carrier or drug delivery system, for example to enhance stability and / or solubility, or to further enhance bioavailability. The composition may be a lyophilized or spray-dried composition.

[0133] The composition may be in the form of a dosage unit, such as a tablet, hi some embodiments, the mass of the dosage unit is in the range of 50 mg to 1000 mg, such as in the range of 50 to 750 mg, or such as in the range of 100 to 500 mg.

[0134] In some embodiments, the mass of a dosage unit is in the range of 75 mg to 350 mg, such as in the range of 100 to 300 mg or such as in the range of 200 to 350 mg.

[0135] In some embodiments, the mass of a dosage unit is in the range of 100 mg to 400 mg, such as in the range of 50 to 300 mg or such as in the range of 200 to 400 mg.

[0136] In some embodiments, the composition can be granulated prior to compression. The composition can include an intragranular portion and / or an extragranular portion, where the intragranular portion is granulated and the extragranular portion is added after granulation.

[0137] The intragranular portion can include a GLP-1 agonist, a delivery agent, and / or excipients such as a lubricant and / or a glidant, hi some embodiments, the intragranular portion includes a delivery agent and a lubricant and / or a glidant.

[0138] The extragranular portion may comprise a GLP-1 agonist and / or a lubricant and / or glidant, such as magnesium stearate. In some embodiments, the extragranular portion comprises a GLP-1 agonist. In some embodiments, the extragranular portion comprises an excipient, for example a lubricant and / or glidant, such as magnesium stearate.

[0139] In a further embodiment, the intragranular portion comprises a GLP-1 agonist, a delivery agent, and a lubricant and / or a glidant. In such an embodiment, the granulation can be directly compressed into a tablet and the tablet has no extragranular portion.

[0140] Preparation of the Composition The preparation of the compositions according to the invention can be carried out according to methods known in the art.

[0141] To prepare a dry blend of the tableting materials, the various ingredients are weighed, optionally de-lumped or sieved, and then combined. Mixing of the ingredients may be carried out until a homogenous blend is obtained.

[0142] When granules are used in the tableting material, they can be prepared in a manner known to those skilled in the art, for example, using wet granulation methods known for the production of "built-up" or "broken-down" granules. The process for forming built-up granules can be operated continuously and simultaneously, for example, by spray drying, spray granulation or spray consolidation, for example, in a drum granulator, in a pan granulator, on a disk granulator, in a fluidized bed, spraying the granulation mass with a granulation liquid and drying. Alternatively, the process for forming built-up granules can be operated discontinuously, for example, in a fluidized bed, in a rotating fluid bed, in a batch mixer such as a high shear mixer or a low shear mixer, or in a spray-drying drum. The process for producing broken-down granules can be carried out discontinuously, where the granulation mass first forms wet agglomerates with the granulation liquid, which are subsequently milled or otherwise formed into granules of the desired size, and the granules can then be dried. Suitable equipment for the wet granulation process are planetary mixers, low shear mixers, high shear mixers, extruders and spheronizers, such as those manufactured by Loedige, Glatt, Diosna, Fielder, Collette, Aeschbach, Alexanderwerk, Ytron, Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva, and Gabler. Granules may also be formed by dry granulation techniques, in which one or more of the excipients and / or active pharmaceutical ingredients are compressed to form relatively large bodies, such as slugs or ribbons, which are broken down by grinding, and the ground material is used as tableting material for subsequent compression. Suitable equipment for dry granulation is roller-type compression equipment manufactured by Gerteis, such as, but not limited to, Gerteis MICRO-PACTOR, MINI-PACTOR, and MACRO-PACTOR.

[0143] The terms "granulation" and "granules" are used interchangeably herein and refer to particles of composition material, which can be prepared as described above.

[0144] Tableting presses may be used to compress tableting materials into solid oral dosage forms, such as tablets. In tableting presses, tableting materials are loaded (e.g., force-fed or gravity-fed) into a die cavity. The tableting materials are then compressed by a set of punches under pressure. The resulting compressed product, i.e., tablet, is then removed from the tableting press. The above-mentioned tableting process is hereinafter referred to as the "compression process". Suitable tableting machines include, but are not limited to, rotary tableting machines and eccentric tableting machines. Examples of tableting machines include, but are not limited to, Fette 102i (Fette GmbH), Korsch XL100, Korsch PH 106 rotary tableting machine (Korsch AG, Germany), Korsch EK-O eccentric tableting machine (Korsch AG, Germany) and Manesty F-Press (Manesty Machines Ltd., UK).

[0145] In one embodiment, the composition comprises at least one granulation. In one embodiment, the composition comprises one type of granulation. Alternatively, the composition may comprise two types of granulation.

[0146] In some embodiments, the method of preparing a tablet comprises: a) granulating a mixture containing a delivery agent and optionally a lubricant; b) blending the granulation of a) with a GLP-1 agonist and optionally further lubricant, and then c) compressing the blend of b) into a tablet.

[0147] In some embodiments, a method for preparing a tablet comprises: a) granulating a mixture comprising a delivery agent, a GLP-1 agonist and optionally a lubricant, and b) compressing the granulation of a) into a tablet and optionally including additional lubricant.

[0148] In general, the granulations can be prepared by wet, melt or dry granulation, preferably dry granulation.

[0149] Indications for the pharmaceutical composition The present invention also relates to the composition of the invention for use as a medicament. In a particular embodiment, the composition of the invention can be used for the following medical treatments, preferably all related in any way to diabetes and / or obesity: (i) For the prevention and / or treatment of all forms of diabetes, such as hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetes of the young), gestational diabetes, and / or for the reduction of HbA1C; (ii) the progression of diabetes, e.g., delaying or preventing progression in type 2 diabetes, delaying the progression of impaired glucose tolerance (IGT) to insulin-requiring type 2 diabetes, and / or delaying the progression of non-insulin-requiring type 2 diabetes to insulin-requiring type 2 diabetes; (iii) improving β-cell function, e.g., reducing β-cell apoptosis, increasing β-cell function and / or β-cell mass, and / or restoring glucose sensitivity to β-cells; (iv) prevention and / or treatment of cognitive impairment; (v) prevention and / or treatment of eating disorders such as obesity, for example by reducing food intake, reducing weight, suppressing appetite, inducing satiety; treatment or prevention of binge eating disorder, bulimia nervosa, and / or obesity induced by the administration of antipsychotics or steroids; reducing gastric motility; and / or slowing gastric emptying; (vi) Prevention and / or treatment of diabetic complications such as neuropathy, including peripheral neuropathy; nephropathy; or retinopathy; (vii) Improvement of lipid parameters, such as prevention and / or treatment of dyslipidemia, lowering total serum lipids; lowering HDL; lowering low density LDL; lowering VLDL; lowering triglycerides; lowering cholesterol; increasing HDL; reducing plasma levels of lipoprotein a (Lp(a)) in humans; inhibiting the production of apolipoprotein a (apo(a)) in vitro and / or in vivo; (iix) prevention and / or treatment of cardiovascular disease, for example, syndrome X; atherosclerosis; myocardial infarction; coronary heart disease; stroke; cerebral ischemia; early cardiac or cardiovascular disease such as left ventricular hypertrophy; coronary artery insufficiency; essential hypertension; acute hypertensive emergency; cardiomyopathy; heart failure; exercise tolerance; chronic heart failure; arrhythmia; cardiac rhythm disorders; syncope; atherosclerosis; mild chronic heart failure; angina pectoris; cardiac bypass reocclusion; intermittent claudication (arteriosclerotic obliterative disease); diastolic dysfunction; and / or systolic dysfunction; (ix) prevention and / or treatment of gastrointestinal disorders, such as inflammatory bowel syndrome; small bowel syndrome or Crohn's disease; dyspepsia; and / or gastric ulcers; (x) Prevention and / or treatment of serious illness, such as treatment of critically ill patients, critically ill polynephropathy (CIPNP) patients, and / or potential CIPNP patients; prevention of serious illness or onset of CIPNP; To prevent, treat, and / or cure systemic inflammatory response syndrome (SIRS) in a patient; and / or to prevent or reduce the likelihood that a patient will suffer from bacteremia, sepsis, and / or septic shock during a hospital stay; and / or (xi) Prevention and / or treatment of Polycystic Ovary Syndrome (PCOS).

[0150] In certain embodiments, the indication is selected from the group consisting of (i)-(iii) and (v)-(iix), such as from the group consisting of indication (i), (ii), and / or (iii), or indication (v), indication (vi), indication (vii), and / or indication (iix). In another particular embodiment, the indication is (i). In a further particular embodiment, the indication is (v). In an even more particular embodiment, the indication is (iix). In some embodiments, the indication is type 2 diabetes and / or obesity.

[0151] Treatment Method The present invention further relates to a method of treating a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a composition according to the invention. In one embodiment, the method of treatment is for the treatment of diabetes or obesity and / or the further indications identified above.

[0152] In some embodiments, a method for treating diabetes is described, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), and optionally a lubricant.

[0153] In some embodiments, a method for treating diabetes is described that includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising 0.5-50 mg of a GLP-1 agonist, 50-500 mg of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), and 1-10 mg of a lubricant. In a preferred embodiment, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid comprises at least 90% (w / w) of the composition.

[0154] In a preferred embodiment, the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 95% (w / w) of the excipients of the composition.

[0155] In an alternative embodiment, a method for treating diabetes is described comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising about 1-14 mg of a GLP-1 agonist, about 100-300 mg of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), and about 2-8 mg of magnesium stearate.

[0156] In some embodiments, the GLP-1 agonist is semaglutide, which has the formula N-epsilon 26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37), and the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). Various examples of lubricants are described, including magnesium stearate. The composition is administered orally and is in the form of a tablet, capsule or sachet.

[0157] In further such embodiments, one or more dosage units may be administered to the subject in need thereof.

[0158] Combination treatment Treatment with the composition according to the invention may also be in combination with one or more further active pharmaceutical ingredients, for example selected from antidiabetic agents, antiobesity agents, appetite control agents, antihypertensive agents, agents for the treatment and / or prevention of complications resulting from or associated with diabetes, agents for the treatment and / or prevention of complications and disorders resulting from or associated with obesity. Examples of these pharmacologically active substances are; insulin, sulfonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, sodium-glucose-coupled transporter type 2 (SGLT2) inhibitors; canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, tofogliflozin, luseogliflozin, bexagliflozin, remogliflozin etabonate. etabonate and sotagliflozin, in particular dapagliflozin and empagliflozin, inhibitors of hepatic enzymes involved in stimulating gluconeogenesis and / or glycogenolysis, glucose uptake regulators, compounds regulating lipid metabolism, for example antihyperlipidemic agents such as HMG CoA inhibitors (statins), gastrointestinal inhibitory polypeptide (GIP analogues), compounds reducing food intake, RXR agonists, and agents acting on the ATP-dependent potassium channel of beta cells; cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, nateglinide, repaglenide;β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin-converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopryl, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α -blockers, such as doxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, PYY agonists, Y2 receptor agonists, Y4 receptor agonists, mixed Y2 / Y4 receptor agonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, beta3 agonists, oxyntomodulin and analogs, MSH (melanocyte stimulating hormone) agonists, MCH (melanocyte concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, mixed serotonin and noradrenaline compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists agonists, growth hormone, growth hormone releasing compounds, TRH (thyrotropin releasing hormone) agonists, UCP2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptine, doplexin), lipase / amylase inhibitors, RXR (retinoid X receptor) modulators, TRβ agonists: histamine H3 antagonists, gastrointestinal inhibitory polypeptide agonists or antagonists (GIP analogs), gastrin and gastrin analogs;

[0159] The invention described herein is not limited thereto but is further defined by the embodiments described herein below and the claims of this document.

[0160] Embodiment 1. a. GLP-1 agonists and b. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w% of the composition; Pharmaceutical compositions.

[0161] 2. a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, for example at least 95 w / w%, of the excipients of the composition; Pharmaceutical compositions.

[0162] 3. a) GLP-1 agonists and b) Excipients wherein the excipient is i. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and ii. one or more further excipients and The salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, for example at least 95 w / w%, of the excipients of the composition; Pharmaceutical compositions.

[0163] 4. A pharmaceutical composition according to any one of the preceding embodiments 1-3, wherein the composition comprises at least one lubricant.

[0164] 5. a) GLP-1 agonists, b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and c) at least one lubricant A pharmaceutical composition comprising:

[0165] 6. The pharmaceutical composition of embodiments 4 and 5 above, wherein the lubricant is magnesium stearate.

[0166] 7. A pharmaceutical composition according to any one of embodiments 1 to 6, wherein the composition comprises 1-8 mg, such as 2-5 mg or such as 2-3 mg, of magnesium stearate per 100 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

[0167] 8. A pharmaceutical composition according to any one of the preceding embodiments 2-7, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w% of the composition.

[0168] 9. A pharmaceutical composition according to any one of the preceding embodiments 1, 5-8, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 95 w / w% of the composition's excipients.

[0169] 10. A pharmaceutical composition according to any one of embodiments 1 to 9, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of sodium, potassium and / or calcium salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

[0170] 11. A pharmaceutical composition according to any one of embodiments 1 to 10, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

[0171] 12. A pharmaceutical composition according to any one of the preceding embodiments, wherein a dosage unit contains at most 1000 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

[0172] 13. A pharmaceutical composition according to any one of embodiments 1 to 12, wherein the dosage unit contains 0.5 to 50 mg of the GLP-1 agonist.

[0173] 14. The pharmaceutical composition of any one of embodiments 1-13, wherein the GLP-1 agonist has a T1 / 2 of at least 24 hours in minipigs.

[0174] 15. A pharmaceutical composition according to any one of embodiments 1 to 14, wherein the GLP-1 agonist has an EC50 (without HSA) of at most 100 pM, such as at most 50.

[0175] 16. A pharmaceutical composition described in any one of embodiments 1 to 15, wherein the GLP-1 agonist is selected from the group consisting of: liraglutide, semaglutide, GLP-1 agonist B and GLP-1 agonist C.

[0176] 17. A pharmaceutical composition described in any one of embodiments 1 to 16, wherein the GLP-1 agonist is selected from the group consisting of: semaglutide and GLP-1 agonist C.

[0177] 18. A pharmaceutical composition described in any one of embodiments 1 to 17, wherein the composition comprises at least one granulation.

[0178] 19. The pharmaceutical composition of embodiment 18 above, wherein at least one granulation comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.

[0179] 20. A pharmaceutical composition according to any one of the preceding embodiments 18 or 19, wherein at least one granulation further comprises a lubricant, such as magnesium stearate.

[0180] 21. A pharmaceutical composition according to any one of the preceding embodiments 18 to 20, wherein at least one granulation further comprises a GLP-1 agonist.

[0181] 22. The pharmaceutical composition of any one of the previous embodiments 18-21, wherein at least one granulation is prepared by dry granulation, such as by roller compaction.

[0182] 23. The pharmaceutical composition of any one of the preceding embodiments 18-22, wherein the composition comprises an extragranular portion.

[0183] 24. A pharmaceutical composition according to any one of the preceding embodiments 18 to 23, wherein the extragranular portion of the composition comprises a lubricant or glidant, such as magnesium stearate, and / or a GLP-1 agonist.

[0184] twenty five. a) GLP-1 agonist 0.5-50 mg and b) 20-800 mg, for example 25-600 mg, for example 50-500 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0185] 26. a) 1 to 25 mg of a GLP-1 agonist and b) 50-400 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0186] 27. a) 1 to 15 mg of a GLP-1 agonist and b) 75-150 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0187] 28. a) 1 to 15 mg of a GLP-1 agonist and b) 75-125 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0188] 29. a) 1 to 15 mg of a GLP-1 agonist and b) 80-120 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0189] 30. a) 1 to 15 mg of a GLP-1 agonist and b) 200-400 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0190] 31. a) 1 to 15 mg of a GLP-1 agonist and b) 250-350 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition and the GLP-1 agonist is semaglutide.

[0191] 32. a) 0.1 to 25 mg of a GLP-1 agonist and b) 20-800 mg, e.g. 25-600, 50-500 mg, of salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0192] 33. a) 1 to 25 mg of a GLP-1 agonist and b) 50-400 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0193] 34. a) 1 to 15 mg of a GLP-1 agonist and b) 75-150 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0194] 35. c) GLP-1 agonist 1 to 15 mg and d) 75-125 mg of salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0195] 36. c) GLP-1 agonist 1 to 15 mg and d) 80-120 mg of salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0196] 37. a) 1 to 15 mg of a GLP-1 agonist and b) 200-400 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0197] 38. a) 1 to 15 mg of a GLP-1 agonist and b) 250-350 mg of salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 95 w / w% of the composition's excipients and the GLP-1 agonist is GLP-1 agonist C.

[0198] 39. A pharmaceutical composition described in any one of embodiments 25 to 38, further comprising 1 to 10 mg of a lubricant, such as magnesium stearate.

[0199] 40. The pharmaceutical composition of any one of embodiments 25-38, further comprising 1-8 mg, such as 2-5 mg or such as 2-3 mg, of magnesium stearate per 100 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid).

[0200] 41. A pharmaceutical composition described in any one of embodiments 1 to 40, wherein the composition is for oral administration.

[0201] 42. A pharmaceutical composition described in any one of embodiments 1 to 41, wherein the composition is a solid composition.

[0202] 43. A pharmaceutical composition described in any one of embodiments 1 to 42, wherein the composition is a solid composition such as a tablet, capsule or sachet.

[0203] 44. a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, Including, GLP-1 agonist release reaches 85% within 15 minutes or 95% within 30 minutes. Pharmaceutical compositions.

[0204] 45. a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, Including, Dose-corrected exposure at t=30 min is increased relative to the reference composition of F / H of WO2013 / 139694. Pharmaceutical compositions.

[0205] 46. a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, Including, Dose-adjusted exposure (AUC) from t=0 to 30 minutes is increased relative to the reference composition of F / H forms of WO2013 / 139694. Pharmaceutical compositions.

[0206] 47. The pharmaceutical composition according to embodiment 46 above, wherein the dose-corrected exposure (AUC) from T=0 to 30 minutes is increased by at least 1.5-fold, such as at least 2-fold.

[0207] 48. The pharmaceutical composition of any one of embodiments 25-40, further defined by one or more of the features of embodiments 8, 10, 11, 18-24, and 41-47.

[0208] 49. The pharmaceutical composition according to embodiment 44, 45, 46 or 47, further defined by one or more features of embodiments 4, 6 to 24 and 41 to 43.

[0209] 50. A pharmaceutical composition according to any one of embodiments 1 to 49 for use in medicine.

[0210] 51. A pharmaceutical composition according to any one of embodiments 1 to 50 for use in a method for treating diabetes and / or obesity.

[0211] 52. A method of treating a subject in need thereof, comprising administering to the subject a therapeutically active amount of a composition described in any one of embodiments 1-51.

[0212] Further embodiments 1. a. GLP-1 agonists and b. Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Including, said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 95 w / w% of the excipients of the composition; Pharmaceutical compositions.

[0213] 2. The pharmaceutical composition described in embodiment 1, further comprising at least one lubricant.

[0214] 3. a) GLP-1 agonists, b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and c) at least one lubricant A pharmaceutical composition comprising:

[0215] 4. A pharmaceutical composition described in any one of embodiments 1 to 3, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes more than 90 w / w% of the composition.

[0216] 5. A pharmaceutical composition according to any one of the preceding embodiments 2-4, wherein the lubricant is magnesium stearate.

[0217] 6. The dosage unit is: a) 0.5 to 50 mg of a GLP-1 agonist and / or b) 50 to 500 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 6. The pharmaceutical composition according to any one of embodiments 1 to 5, comprising:

[0218] 7. The dosage unit is: a) 0.5 to 50 mg of a GLP-1 agonist, b) 50 to 500 mg of the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and c) 1 to 10 mg of a lubricant, such as magnesium stearate 7. The pharmaceutical composition according to any one of embodiments 1 to 6, comprising:

[0219] 8. A pharmaceutical composition described in any one of embodiments 1 to 7, wherein the GLP-1 agonist is selected from the group consisting of: liraglutide, semaglutide, GLP-1 agonist B and GLP-1 agonist C.

[0220] 9. A pharmaceutical composition described in any one of embodiments 1 to 8, wherein the composition is a solid composition, such as a tablet for oral administration.

[0221] 10. a) GLP-1 agonists and b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, Including, i. the release of the GLP-1 agonist reaches 85% within 15 minutes; and / or ii. the dose-adjusted exposure (AUC) from t=0 to 30 minutes is increased relative to the reference compositions of F / H forms of WO2013 / 139694; and / or iii. The dose-adjusted exposure (AUC) at 30 minutes is increased relative to the reference composition of Form F / H of WO2013 / 139694; Pharmaceutical compositions.

[0222] 11. A pharmaceutical composition according to embodiment 10 having one or more of the features of any one of embodiments 1 to 9.

[0223] 12. A pharmaceutical composition according to any one of embodiments 1 to 11 for use in medicine.

[0224] 13. A pharmaceutical composition according to any one of embodiments 1 to 12 for use in a method for the treatment of diabetes and / or obesity.

[0225] 14. A method of treating an individual in need thereof, comprising administering to said individual a therapeutically active amount of a composition according to any one of embodiments 1-13.

[0226] Methods and Examples General Methods of Detection and Characterization Assay I: Dissolution test Dissolution testing may be performed in a suitable dissolution apparatus, e.g. USP dissolution apparatus 2, and standard dissolution tests according to the European Pharmacopoeia (Ph Eur 2.9.3) may be performed to measure the release of the GLP-1 agonist and SNAC in vitro.

[0227] The data described herein are obtained using an apparatus 2 according to USP 35 using a paddle rotation speed of 50 rpm. For testing at pH 6.8, 500 mL dissolution medium of 0.05 M phosphate buffer is used at a temperature of 37±0.5° C. The dissolution medium has a content of 0.1% Brij® 35. Samples are taken at appropriate intervals. The sample content is determined using a RP-HPLC method for dual detection of SNAC and GLP-1 agonist. The sample content is calculated based on the peak area of ​​the SNAC peak and the GLP-1 agonist peak in the chromatogram relative to the peak areas of the SNAC reference and the GLP-1 agonist reference, respectively. The released amount of SNAC and GLP-1 agonist is calculated as a percentage of the actual content in the tablet, i.e. 100 / 200 / 300 mg per tablet for SNAC and 3 / 5 / 4 mg per tablet for GLP-1 agonist (e.g., analog A, B or C). The actual content in the tablets is determined using Assay (II). The amount of GLP-1 agonist released is reported as the average value of three tablets.

[0228] Assay II: Analysis of the amount of GLP-1 agonist and SNAC Tablets are weighed prior to extraction of GLP-1 agonist and SNAC. Tablets are dissolved in an appropriate amount of 0.05M phosphate buffer pH 7.4 containing 20% ​​acetonitrile. An extraction time of 2 hours is used. Samples are centrifuged and appropriate volumes are transferred to HPLC vials. Standard solutions of relevant GLP-1 agonist and SNAC are prepared using the same diluents as the samples. HPLC equipped with UV detector is used for determination of GLP-1 agonist content and SNAC content. Sample content is calculated based on the peak area of ​​the SNAC peak and GLP-1 agonist peak in the chromatogram relative to the peak areas of the SNAC reference and GLP-1 agonist reference, respectively. Content is reported as the average of three tablets.

[0229] Assay III: Pharmacokinetic studies in beagle dogs A pharmacokinetic (PK) study in beagle dogs is conducted to determine the exposure of a GLP-1 agonist following oral administration of various dosage forms.

[0230] For pharmacokinetic studies, male beagle dogs, 1-5 years old, weighing approximately 10-12 kg at the start of the study, are used. Dogs are group-housed in cages (12-h light:12-h dark) and individually fed once-daily restrictively in Royal Canin Medium Adult Dog Foods (Royal Canin Products, China Branch or Brogaarden A / S, Denmark). Exercise and group socialization are allowed daily whenever possible. Dogs are used in repeated pharmacokinetic studies with adequate washout periods between successive dosings. An adequate acclimation period is allowed before the start of the first pharmacokinetic study. All animal handling, dosing, and blood sampling are performed by trained and experienced staff. Dogs are fasted overnight before the study and for 0-4 hours after dosing. In addition, dogs are water restricted from 1 hour before dosing until 4 hours after dosing, otherwise they have free access to water throughout the entire period.

[0231] The GLP-1 agonist tablets used in the po studies described herein are immediate release SNAC-based tablets administered orally.

[0232] Tablets containing GLP-1 agonists are administered in the following manner: 10 minutes before tablet administration, dogs are given approximately 3 nmol / kg of SEQ ID NO: 3 subcutaneously. The GLP-1 tablet is placed at the back of the dog's mouth to prevent chewing. The mouth is then closed and 10 mL or 50 mL of tap water is given by syringe or tube administration to facilitate swallowing of the tablet.

[0233] blood sampling Blood is collected at pre-determined time points up to 10 hours post-dose to adequately cover the entire plasma concentration-time absorption profile of the GLP-1 agonist. At each blood collection time point, approximately 0.8 mL of whole blood is collected into a 1.5 mL EDTA-coated tube and the tube is gently swirled to mix the sample with the EDTA. Blood samples (e.g., 0.8 mL) are collected in EDTA buffer (8 mM) and then centrifuged at 4°C and 2000G for 10 minutes. Plasma is pipetted into Micronic tubes on dry ice and kept at -20°C until analysis. Blood samples are taken with a syringe as needed, for example from a venflon in the cephalic vein of the forelimb for the first 2 hours, then from the jugular vein for the remaining time points (allowing the first few drops to drain from the venflon to avoid heparinized saline from the venflon to the sample).

[0234] General method for tablet preparation Method 1: Dry granulation Dry granulation is carried out by roller compaction in a Gerteis MICRO-PACTOR. The roll speed is set at 1 rpm, the roller compaction force is set at 6 kN / cm, and the packing depth is 8 mm. Dry granulation is followed by manual sieving of the ribbons into granules by using a 0.8 mm wire mesh screen. Optionally, a second sieving step is applied on a Retch oscillating screen to remove fines, using a 90 μm screen.

[0235] Method 2: Tablet preparation Tablets are made on a Kilian Style One or Fette 102I equipped with a single or four sets of punches to obtain unbroken 4mm round tablets, 7mm round tablets or 5.75x10mm, 7.2x12mm, 7.5x12.5mm or 9x18mm oval tablets. The punch size is selected depending on the total tablet mass. For the Kilian Style One, the press speed is set at 10% and for the Fette 102I, the press speed is set at 20 rpm. The filling capacity is adjusted to obtain tablets with a target mass of 28.6mg to 823.5mg. A compression force of approximately 2-15kN is applied to obtain tablets with a crushing strength of approximately 20-160N depending on the tablet size. EXAMPLES

[0236] Example 1 Preparation of the composition Tablets containing various amounts of GLP-1 agonist, SNAC and further excipients were prepared. The contents of the prepared compositions are provided in Table 1 (Table 1.1, Table 1.2 and Table 1.3). GLP-1 agonist A is semaglutide, GLP-1 agonist B is diacylated [Aib8, Arg34, Lys37] GLP-1 (7-37) (Example 2 of WO2011 / 080103) and GLP-1 agonist C is diacylated-[Aib8, Glu22, Arg26, Lys27, Glu30, Arg34, Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly (Example 31 of WO2012 / 140117). Semaglutide can be prepared according to the method described in WO2006 / 097537, Example 4. GLP-1 agonists B and C can be prepared as described in WO2011 / 080103 and WO2012 / 140117, respectively. SNAC was prepared according to the method described in WO2008 / 028859.

[0237] Reference compositions A, B and C were generally prepared as described in WO2013 / 139694. Test compositions (A1, A2, B1-B4, C1 and C2) were generally prepared as described in Methods 1 and 2 above, with minor modifications to the process prior to roller compaction and tablet preparation, as specified below.

[0238] [Table 1]

[0239] [Table 2]

[0240] [Table 3]

[0241] To prepare test compositions A1, A2, B1, B3, C1 and C2, the following procedure was followed; granular magnesium stearate was sieved through a 355 μm or finer sieve. The exact amounts of magnesium stearate and SNAC were weighed out. Magnesium stearate was mixed manually with SNAC according to the geometric mixing principle. Two cycles of geometric dilution were applied. The remaining amount of SNAC was transferred to a mixing vessel and mixed with the SNAC and magnesium stearate premix in a Turbula mixer at 25 rpm for 30 minutes. The blend was roller compacted as described in Method 1.

[0242] The exact amount of GLP-1 agonist and SNAC magnesium stearate granules were weighed out. The SNAC magnesium stearate granules were added to a mixing vessel and mixed manually with the GLP-1 agonist according to the geometric mixing principle. Two cycles of geometric dilution were applied. The remaining amount of SNAC magnesium stearate granules was transferred to the mixing vessel. Final mixing of the GLP-1 agonist and granules was performed in a Turbula mixer for 7 minutes at 25 rpm or 20 minutes at 25 rpm. Tablets were prepared from this composition according to method 2.

[0243] B2 was prepared as follows; the magnesium stearate and SNAC granules were prepared as described for the previous test composition. The exact amount of SNAC and magnesium stearate granules and GLP-1 agonist were weighed. 1 / 3 of the SNAC and magnesium stearate granules were mixed with the GLP-1 agonist by adding the granules to a mixing vessel according to the geometric mixing principle. A Turbula mixer was applied for 7 minutes at 25 rpm. Two cycles of geometric dilution were applied. The remaining amount of the SNAC and magnesium stearate granules was transferred to a mixing vessel and mixed according to the geometric mixing principle. A final mixing of the GLP-1 agonist and granules was performed in a Turbula mixer for 7 minutes at 25 rpm. Tablets were prepared from this composition according to method 2.

[0244] B4 was prepared as follows; SNAC granules (without magnesium stearate) were prepared as described for the previous test composition and in method 1. The exact amount of GLP-1 agonist and SNAC granules were weighed out. The SNAC granules were added to the mixing vessel and mixed with the GLP-1 agonist according to the geometric mixing principle. Two cycles of geometric dilution were applied. The remaining portion of SNAC granules was added to the mixing vessel. Mechanical mixing of the GLP-1 agonist and granules was performed in a Turbula mixer at 25 rpm for 7 minutes. Glyceryl dibehenate (Compritol 888 ATO) was sieved to 350 μm or less. The exact amount of glyceryl dibehenate was weighed out. The glyceryl dibehenate was manually mixed with the mixture of SNAC granules and GLP-1 agonist according to the geometric mixing principle. Three cycles of geometric dilution were applied. The resulting mixture was transferred to a mixing vessel along with the remaining SNAC granules and the mixture with the GLP-1 agonist. Final mixing with Compritol 888 ATO was performed in a Turbula mixer at 25 rpm for 2 minutes. Tablets were prepared from this composition according to Method 2.

[0245] Example 2 -Dissolution test The objective of this study was to evaluate the dissolution of a series of tablet compositions described in Example 1.

[0246] Dissolution was measured according to Assay I. Table 2 shows the results for tablets prepared according to Example 1 above, where the release is presented as "GLP-1 agonist in solution (%)", which represents the amount of GLP-1 agonist in solution after 15, 30 and 60 minutes relative to the total amount of GLP-1 agonist in the tablet at the start of the experiment. The total amount of GLP-1 agonist and SNAC in the tablets was determined according to Assay II.

[0247] [Table 4]

[0248] The results show that the test composition exerts a faster release of the GLP-1 agonist compared to that observed with the reference composition. A significantly faster release of the GLP-1 agonist is observed for earlier time points, i.e., 15 and 30 minutes. The difference in release is smaller after 60 minutes. The amount of SNAC in the tablet does not affect the release of the GLP-1 agonist, i.e., a tablet containing 100 mg of SNAC dissolves as quickly as a tablet containing 300 mg of SNAC when measured after 15 minutes.

[0249] Further data obtained for Composition A1 and Reference A after 5, 10, 15, 20, 30, 45 and 60 minutes is shown in Figure 1 and demonstrates enhanced release at all time points.

[0250] Example 3 -Oral exposure The purpose of this study was to evaluate the oral exposure in beagle dogs for a series of compositions described in Example 1 above using 10 ml of water for administration to beagle dogs. The number of tests performed for each formulation is indicated by n.

[0251] Analysis and Results Plasma concentrations of each GLP-1 agonist were analyzed using ELISA or similar antibody-based assays such as LOCI. Individual plasma concentration-time profiles were analyzed by non-compartmental models in WinNonlin v. 5.0 or Phoenix v. 6.2 or 6.3 (Pharsight Inc., Mountain View, CA, USA) or other relevant software for PK analysis.

[0252] Compound exposure was determined at t=30 min and normalized by dose / kg body weight.

[0253] The area under the plasma concentration versus time curve (AUC, [time x concentration]) for the first 30 min was calculated after oral administration (by the Pharsight program) and normalized by ((dose / kg body weight)*100) to obtain dose-corrected exposure. The resulting mean values ​​are provided in table 3.1.

[0254] The mean dose-corrected exposures for Analogs A, B and C at t=0, 5, 10, 15, 20 and 30 minutes obtained with Formulation A1, Reference A, B1 and Reference B, C1 and Reference C are shown in FIG.

[0255] Since individual GLP-1 agonists behave differently, i.e., some may have higher or lower general bioavailability, it may also be important to compare relative exposure to understand the effect of a particular dosage form / dosage unit compared to the effect of a different dosage form / dosage unit containing the same GLP-1 agonist. Such results are contained in table 3.2, which shows that a 2-fold increase in exposure during the first 30 minutes was obtained using the dosage forms disclosed herein compared to the reference dosage form of each GLP-1 agonist.

[0256] [Table 5]

[0257] [Table 6]

[0258] Example 4 - Oral exposure to SNAC tablets 25-800 mg Further tablets with increasing and decreasing amounts of SNAC were prepared as above for A1 and A2.

[0259] A5 has the same composition as A2 above. Again, the granules were prepared by dry granulation using a MINI-PACTOR® followed by removal of fines using a 90 μm sieve screen. SNAC and magnesium stearate were mixed in a V-shell at 25 rpm for 50 minutes before dry granulation. The granules of SNAC and magnesium stearate were mixed with the GLP-1 agonist in a V-shell at 25 rpm for 10 minutes before tablet compression according to method 2. For composition A7, GLP-1 agonist A was dry granulated with SNAC and magnesium stearate using a MINI-PACTOR® followed by removal of fines using a 90 μm sieve screen. SNAC and magnesium stearate were mixed in a V-shell at 25 rpm for 50 minutes, then GLP-1 was added before dry granulation and mixed at 25 rpm for 20 minutes. The granules were then compressed into tablets according to method 2. For compositions A5 and A7, the MINI-PACTOR was operated with a compression force of 6 kN / cm, a gap of 1 mm, a roll speed of 3 rpm and equipped with a wire mesh screen of 0.63 μm.

[0260] [Table 7]

[0261] The objective of this study was to evaluate the oral exposure in beagle dogs for a series of compositions listed in Table 4. Oral exposure was evaluated in beagle dogs as described in Example 1 above, using 50 ml of water for administration to the dogs. The number of tests performed for each formulation is indicated by n.

[0262] The results were analyzed as described in Example 3, and the resulting average values ​​are provided in table 4.2 (Table 8) and the relative values ​​are provided in table 4.3 (Table 9) below.

[0263] [Table 8]

[0264] [Table 9]

[0265] The data confirms that increased exposure is obtained in the first 30 minutes using the dosage forms disclosed herein compared to the reference dosage form.

Claims

1. a) 0.5-50 mg of a GLP-1 agonist and b) 20 to 800 mg, for example 50 to 500 mg, of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and c) Lubricant 0.6-20 mg, e.g. 1-10 mg Including, A pharmaceutical composition, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w%, such as at least 95 w / w%, of the excipients of the composition.

2. 2. The pharmaceutical composition of claim 1, wherein the lubricant is magnesium stearate or glyceryl dibehenate.

3. a) GLP-1 agonists, b) Salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and c) at least one lubricant The pharmaceutical composition according to claim 1 or 2, comprising:

4. 4. The pharmaceutical composition according to claim 1, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w / w% of the composition.

5. 5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the composition comprises 1 to 8 mg, such as 2 to 5 mg or such as 2 to 3 mg, of magnesium stearate per 100 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid).

6. GLP-1 agonists include GLP-1 peptides substituted with fatty acids or fatty diacids, For example, semaglutide, N ε26 {2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}-ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl},N ε37 -{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}-ethoxy)ethoxy]-acetyl}-[Aib 8 ,Arg 34 ,Lys 37 ]GLP-1(7-37)-peptide (GLP-1 agonist B) and N ε27 -[2-[2-[2-[[2-[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]-amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]-acetyl], N ε36 6. The pharmaceutical composition of claim 1, wherein the GLP-1 agonist is selected from the group consisting of -[2-[2-[[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]-amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27,Glu30,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly (GLP-1 agonist C).

7. 7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).

8. The dosage unit is a) Semaglutide 0.5-20mg, b) SNAC 50-400mg and c) Lubricant 1-10mg 8. The pharmaceutical composition according to any one of claims 1 to 7, comprising:

9. The dosage unit is a) Semaglutide 1-10mg, b) SNAC 50-300mg and c) Magnesium stearate 1-10 mg 9. The pharmaceutical composition according to any one of claims 1 to 8, comprising:

10. The dosage unit is a) GLP-1 agonist C 0.5-20 mg, b) SNAC 50-400mg and c) Lubricant 1-10mg 7. The pharmaceutical composition according to any one of claims 1 to 6, comprising:

11. The dosage unit is a) GLP-1 agonist C 1-10 mg; b) SNAC 50-300mg and c) Magnesium stearate 1-10 mg 7. The pharmaceutical composition according to any one of claims 1 to 6, comprising:

12. 12. The pharmaceutical composition of claim 1, wherein the composition is a solid composition, such as a tablet for oral administration.

13. 13. A pharmaceutical composition according to any one of claims 1 to 12 for use in medicine.

14. 14. A pharmaceutical composition according to any one of claims 1 to 13 for use in a method for the treatment of diabetes and / or obesity.

15. 15. A method of treating a subject in need thereof comprising administering to the subject a therapeutically active amount of the composition of any one of claims 1 to 14.